Get the Stockscreener App
3.40
0.59%
0.02
Neuronetics Inc stock is traded at $3.40, with a volume of 1.90M.
It is up +0.59% in the last 24 hours and down -19.43% over the past month.
Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulations, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options.
See More
Previous Close:
$3.38
Open:
$3.38
24h Volume:
1.90M
Relative Volume:
1.99
Market Cap:
$224.82M
Revenue:
$69.23M
Net Income/Loss:
$-33.10M
P/E Ratio:
-2.8814
EPS:
-1.18
Net Cash Flow:
$-39.26M
1W Performance:
+1.80%
1M Performance:
-19.43%
6M Performance:
-17.68%
1Y Performance:
+248.97%
1-Day Range:
$3.29
$3.51
1-Week Range:
$3.20
$3.80
52-Week Range:
$0.52
$5.92
Neuronetics Inc Stock (STIM) Company Profile
Name
Neuronetics Inc
Sector
Industry
Phone
877-600-7555
Address
3222 PHOENIXVILLE PIKE, MALVERN, PA
Compare STIM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
STIM
Neuronetics Inc
|
3.40 | 234.08M | 69.23M | -33.10M | -39.26M | -1.18 |
|
ABT
Abbott Laboratories
|
132.59 | 226.73B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
106.17 | 152.69B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
394.22 | 145.89B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.71 | 118.91B | 33.54B | 4.69B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
81.83 | 45.97B | 5.69B | 1.41B | 577.90M | 6.95 |
Neuronetics Inc Stock (STIM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-13-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-13-21 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-13-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jan-22-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Feb-06-20 | Initiated | BTIG Research | Buy |
| Jul-24-18 | Initiated | Canaccord Genuity | Buy |
View All
Neuronetics Inc Stock (STIM) Latest News
What makes Neuronetics Inc. stock price move sharplyDollar Strength & AI Powered Market Entry Strategies - thegnnews.com
Can Neuronetics Inc. expand into new markets2025 Breakouts & Breakdowns & Weekly Sector Rotation Insights - sundaytimes.kr
Is Neuronetics Inc. stock showing strong momentumQuarterly Trade Report & Growth Focused Stock Reports - mustnews.co.kr
Is Neuronetics Inc. forming a bullish divergenceJuly 2025 Catalysts & Community Verified Trade Alerts - thegnnews.com
Short Covering May Lift Neuronetics Inc. in Near TermPortfolio Return Summary & AI Driven Stock Movement Reports - beatles.ru
Neuronetics Inc. Price Holds Above Key Fib LevelMarket Trend Summary & Low Drawdown Investment Strategies - newsimpact.co.kr
Neuronetics’ SWOT analysis: navigating growth in mental health tech stock - Investing.com India
Neuronetics’ SWOT analysis: navigating growth in mental health tech stock By Investing.com - Investing.com Nigeria
Neuronetics Stock Soars 7.25% on Institutional Investments - AInvest
Major Stakeholder Sells Millions in Neuronetics Stock! - TipRanks
How does Neuronetics Inc. compare to its peersFastest Growing Stock Radar - mustnews.co.kr
Neuronetics Study Shows Strong Antidepressant Results for Teens and Young Adults Using NeuroStar TMS - MSN
Neuronetics Issues Inducement Equity Awards to New Hires - MSN
Neuronetics Price Target Adjusted Down to $7, Analyst Maintains Buy Rating - AInvest
It's Down 25% But Neuronetics, Inc. (NASDAQ:STIM) Could Be Riskier Than It Looks - 富途牛牛
Neuronetics shares fall 3.42% intraday after granting inducement awards to new employees. - AInvest
Neuronetics Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Here's What Analysts Are Forecasting For Neuronetics, Inc. (NASDAQ:STIM) After Its Second-Quarter Results - simplywall.st
Neuronetics announces inducement grant - Medical Buyer
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Neuronetics Expands Leadership Team with 31,650 RSU Grants: Major Push in Neurohealth Tech - Stock Titan
Neuronetics (STIM): Canaccord Genuity Adjusts Price Target | STI - GuruFocus
Neuronetics: Canaccord Genuity maintains Buy, PT down to $7 from $8. - AInvest
Neuronetics adjusts 2025 gross margin guidance to 48%-50% as Greenbrook revenue mix rises - MSN
Neuronetics Takes A Leap In Mental Health Tech - Finimize
Neuronetics, Inc. (NASDAQ:STIM) Q2 2025 Earnings Call Transcript - Insider Monkey
Canaccord Genuity lowers Neuronetics stock price target on margin concerns By Investing.com - Investing.com Canada
Canaccord Genuity lowers Neuronetics stock price target on margin concerns - Investing.com
Neuronetics (STIM) Price Target Reduced by Canaccord Analyst - GuruFocus
Neuronetics Reports Q2 2025 Financial Results Surge - The Globe and Mail
Neuronetics: Q2 Earnings Snapshot - Greenwich Time
Neuronetics 2025 Q2 Earnings Beats Expectations as Net Loss Narrows 54.5% - AInvest
Neuronetics Inc (STIM) Q2 2025 Earnings Call Highlights: Record Revenue Growth Amid Strategic Shifts - GuruFocus
Neuronetics Inc (STIM) Q2 2025 Earnings Call Highlights: Record Revenue Growth Amid Strategic Shifts By GuruFocus - Investing.com Canada
Neuronetics Reports Revenue Growth Amid Greenbrook Acquisition - TipRanks
Neuronetics’ Earnings Call: Revenue Growth Amid Challenges - TipRanks
Neuronetics' 2025 Gross Margin Guidance: A Calculated Path to Profitability Amid Integration Challenges - AInvest
Neuronetics Q2 2025: Navigating Contradictions in Marketing Strategies and Revenue Expectations - AInvest
Earnings call transcript: Neuronetics Q2 2025 Misses EPS Forecast, Stock Drops - Investing.com
Neuronetics Q3 Revenue Forecast $37M-$39M, Close to Consensus Estimate of $38.22M - AInvest
Neuronetics 2025 Financial Forecast: Revenue Ranges from $149M to $155M, Gross Margin at 48%-50% - AInvest
Neuronetics Q3 Revenue Outlook: $37M-$39M vs. Consensus $38.22M - AInvest
Neuronetics (STIM) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Neuronetics Reports Second Quarter 2025 Financial and Operating Results | STIM Stock News - GuruFocus
Neuronetics Q2 2025 slides reveal strong revenue growth, path to profitability - Investing.com
Neuronetics Q2 Financial Results: $10.1 Million Loss ReportedNews and Statistics - IndexBox
Neuronetics earnings missed by $0.07, revenue topped estimates - Investing.com
Neuronetics' Q2 2025 Earnings: A Tale of Two Metrics – Revenue Growth vs. Persistent Losses - AInvest
Neuronetics, Inc. SEC 10-Q Report - TradingView
Neuronetics Reports Second Quarter 2025 Financial and Operating Results - The Globe and Mail
Healthcare firm Neuronetics Q2 revenue misses estimates - MarketScreener
Neuronetics Inc Stock (STIM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.89%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):